IP Library Granted Patent US 8,574,622
Granted Patent B2
US 8,574,622 · App. 13/194,928 · Granted Nov 5, 2013

Controlled release delivery system for nasal applications

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,574,622
App. No.
13/194,928
Granted
Nov 5, 2013
Kind
B2
Abstract

This invention relates to a pernasally administrable preparation for the controlled release of sexual hormones to the systemic circulation, in particular to a formulation which enables its active ingredient to be absorbed in a sustained manner providing a better bioavailability at very low doses and longer duration of action.

Claims (16)

1. A testosterone gel formulation for nasal administration to a patient for controlled release of testosterone into systemic circulation of the patient following the nasal administration for treating the patient with testosterone therapy, the testosterone gel formulation comprising:

(a) testosterone, wherein said testosterone is present within the testosterone gel formulation in an amount of from about 0.5% to about 10% by weight of the testosterone gel formulation:

(b) at least one lipophilic or partly lipophilic carrier present in an amount of from about 60% to about 98% by weight of the testosterone gel formulation;

(c) a compound or a mixture of compounds having surface tension decreasing activity present in an amount of from about 1% to about 20% by weight of the testosterone gel formulation; and

(d) a viscosity regulating agent present in an amount of from about 0.5% to about 10% by weight of the testosterone gel formulation.

2. The testosterone gel formulation according to claim 1 , wherein said lipophilic carrier comprises an oil.

3. The testosterone gel formulation according to claim 2 , wherein said oil is a vegetable oil.

4. The testosterone gel formulation according to claim 3 , wherein said vegetable oil is castor oil.

5. The testosterone gel formulation according to claim 1 , wherein said compound or said mixture of compounds having surface tension decreasing activity comprise an oleoyl macrogolglyceride or a mixture of oleoyl macrogolglycerides.

6. The testosterone gel formulation according to claim 1 , wherein said viscosity regulating agent is colloidal silicon dioxide.

7. A testosterone gel formulation for nasal administration for controlled release of testosterone into systemic circulation of a patient following nasal administration to the patient, the testosterone gel formulation comprising:

(a) testosterone, wherein said testosterone is present within the testosterone gel formulation in an amount of from about 0.5% to about 6% by weight of the testosterone gel formulation;

(b) castor oil in an amount of from about 75% to about 95% by weight of the testosterone gel formulation;

(c) oleoyl macrogolglycerides in an amount of from about 1% to about 5% by weight of the testosterone gel formulation; and

(d) colloidal silicon dioxide in an amount of from about 0.5% to about 5% by weight of the testosterone gel formulation;

wherein the testosterone serum level achieved following the nasal administration of the testosterone gel formulation to the patient is sustained above the patient's testosterone baseline for at least 6 hours.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 9, 2018
From: MIDCAP FUNDING V TRUST
To: ACERUS PHARMACEUTICALS SRL
Reel/Frame 047207/0254 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2017
From: MATTERN PHARMA AG
To: M ET P PHARMA AG
Reel/Frame 041645/0897 →
CORRECTIVE ASSIGNMENT TO CORRECT THE TO CORRECT THE ASSIGNOR FROM M & P PATNT AKTIENGESELLSCHAFT TO M & P PATENT AKTIENGESELLSCHAFT PREVIOUSLY RECORDED ON REEL 032291 FRAME 0349. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER EFFECTIVE 02/04/2014. Recorded Mar 10, 2014
From: M & P PATENT AKTIENGESELLSCHAFT
To: MATTERN PHARMA AG
Reel/Frame 032422/0169 →
MERGER Recorded Feb 25, 2014
From: M & P PATNT AKTIENGESELLSCHAFT
To: MATTERN PHARMA AG
Reel/Frame 032291/0349 →